Tb-500 has more published human clinical data than Bpc-157, including a 40 person safety study showing tolerability up to extremely high doses and a 73 person wound healing study showing 45 percent faster recovery
In clinical use, BPC-157 may support healing in patients whose activities, occupations, or injuries require additional metabolic support
Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
Combining peptide therapy with these practices can enhance its effectiveness and support overall recovery
Its ability to increase blood flow delivers nutrients and healing factors to injured tissues
In addition, the applicant stated that TECVAYLI TM may be more immediately accessible than the BCMA CAR T-cell therapies due to restrictions in site of care, manufacturing complexities, and other concerns with respect to the BCMA CAR T-cell therapies